Yale Medicine School Cancer Center Study Shows New Drug Combinations Improve Outcomes for Patients With Advanced Lung Cancer
September 18, 2021
September 18, 2021
NEW HAVEN, Connecticut, Sept. 18 (TNSRes) -- Yale School of Medicine issued the following news:
New findings from a large study led by researchers at Yale Cancer Center shows the addition of the drugs oleclumab or monalizumab to durvalumab improved progression-free survival for patients with locally advanced non-small cell lung cancer (NSCLC). The data is part of the COAST trial and will be presented on September 17, 2021 at the annual meeting of the European Society for Medical Onc . . .
New findings from a large study led by researchers at Yale Cancer Center shows the addition of the drugs oleclumab or monalizumab to durvalumab improved progression-free survival for patients with locally advanced non-small cell lung cancer (NSCLC). The data is part of the COAST trial and will be presented on September 17, 2021 at the annual meeting of the European Society for Medical Onc . . .